2-Chloro-6-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol → HCID 68298666, compound
Reaction equation
Br[C:2]1[CH:3]=[C:4]2[C:9](=[CH:10][CH:11]=1)[N:8]=[CH:7][C:6]([C:12]([CH:14]1[CH2:16][CH2:15]1)=[O:13])=[C:5]2[NH:17][C:18]1[CH:19]=[N:20][C:21]([N:24]2[CH2:28][CH2:27][CH:26]([NH:29]C(=O)OC(C)(C)C)[CH2:25]2)=[N:22][CH:23]=1.[Cl:37][C:38]1[CH:43]=[C:42](B2OC(C)(C)C(C)(C)O2)[CH:41]=[C:40]([O:53][CH3:54])[C:39]=1[OH:55]>>[NH2:29][CH:26]1[CH2:27][CH2:28][N:24]([C:21]2[N:22]=[CH:23][C:18]([NH:17][C:5]3[C:4]4[C:9](=[CH:10][CH:11]=[C:2]([C:42]5[CH:41]=[C:40]([O:53][CH3:54])[C:39]([OH:55])=[C:38]([Cl:37])[CH:43]=5)[CH:3]=4)[N:8]=[CH:7][C:6]=3[C:12]([CH:14]3[CH2:15][CH2:16]3)=[O:13])=[CH:19][N:20]=2)[CH2:25]1Participants
Procedure
Following general procedure D, tert-butyl 1-(5-(6-bromo-3-(cyclopropanecarbonyl)quinolin-4-ylamino)pyrimidin-2-yl)pyrrolidin-3-ylcarbamate (100 mg, 0.18 mmol) was reacted with 2-chloro-6-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol (77 mg, 0.27 mmol) to obtain the protected intermediate which was subjected to general procedure A-2 to afford the desired product (20 mg, 21% over 2 steps) as a yellow solid: 1H NMR (500 MHz, CD3OD+TFA-d) δ 9.35 (s, 1H), 8.48 (s, 2H), 8.29 (dd, J=8.8, 1.9 Hz, 1H), 8.21 (s, 1H), 8.04 (d, J=8.8 Hz, 1H), 7.09 (s, 1H), 6.89 (s, 1H), 4.04 (m, 2H), 3.94 (s, 3H), 3.89 (m, 1H), 3.79 (m, 2H), 2.82 (s, 1H), 2.52 (ddd, J=14.8, 12.7, 6.4 Hz, 1H), 2.23 (dt, J=11.6, 6.2 Hz, 1H), 1.21 (s, 4H); ESI MS m/z 531 [C28H27ClN6O3+H]+; HPLC 99.9% (AUC), tR=10.11 min.
Workup
- customto obtain the protected intermediate which
Sources & evidence
- ORD record
- ord-8bfec48bfe2b43f3bf81af38489f0465
- Source dataset
- uspto-grants-2015_09
- Patent number
- US09120749B2
Reaction notes
Loading…